UK markets closed
  • NIKKEI 225

    -119.97 (-0.44%)

    +46.30 (+0.19%)

    -0.18 (-0.21%)

    -10.40 (-0.57%)
  • DOW

    -129.64 (-0.38%)

    -138.52 (-0.50%)
  • CMC Crypto 200

    -20.12 (-2.35%)
  • ^IXIC

    +2.82 (+0.02%)
  • ^FTAS

    +53.23 (+1.29%)

The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1%

·3-min read

during the forecast period. Market growth is driven by factors such as the rising incidence & prevalence of cancerand the increasing preference for noninvasive treatment procedures. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.

New York, Dec. 08, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Liquid Biopsy Market by Product, End User - Global Forecast to 2026" -

The assay kits segment accounted for the highest growth rate in theliquid biopsy market, by product& service, during the forecast period
The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service.In 2020, the assay kits segment accounted for the highest growth rate in the liquid biopsy market.

The availability of a wide range of reagents and kits, easy accessibility to a wide range of assays, and the rising prevalence of cancer are the major factors driving the growth of the liquid biopsy assay kits market.

Non-cancer applicationssegment accounted for the highest CAGR
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications.In 2020, the non-cancer application segment accounted for the highest growth rate.

This can be attributed to the increasing research activities in NIPT and organ transplant diagnosis.

Asia Pacific: The fastest-growing regionliquid biopsymarket
The global liquid biopsymarket is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japanare expected to boost the market growth. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Myriad Genetics, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Thermo Fisher Scientific, Inc. (US)
• Guardant Health, Inc. (US)
• MDxHealth SA (Belgium)
• Exact Sciences Corporation (US)
• Illumina Inc. (US)
• Sysmex Inostics (US)
• Bio-Rad Laboratories, Inc. (US)
• Biocept, Inc. (US)
• NeoGenomics, Inc. (US)
• ANGLE plc (UK)
• Menarini-Silicon Biosystems (Italy)
• Vortex Biosciences, Inc. (US)
• Exosome Diagnostics, Inc. (US)
• Agena Bioscience, Inc. (US)
• MedGenome Inc. (US)
• Epigenomics AG (Germany)
• Personal Genome Diagnostics, Inc. (US)

Research Coverage:
This report provides a detailed picture of the global liquid biopsymarket.It aims at estimating the size and future growth potential of the market across different segments, such as product& service, clinical application, technology, circulating biomarkers, application, and end user.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, andchallenges.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting